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ABSTRACT
Objective: To evaluate the value of post-treatment follow-up in 
osteosarcoma patients. Methods: Data were collected through 
a clinical record, with socio-demographic and clinical data, and 
information relating to the medical appointment. Descriptive 
analysis of the data was carried out. The Chi-squared test was 
used to associate the independent variables with attendance 
at scheduled follow-up appointments. Results: We found a 
recurrence in 59.6% of cases, of which 58% were lung related; 
44% presented clinical complaints and arrived on the scheduled 
date of the appointment. There was no statistically significant 
association between the demographic characteristics and 
early attendance of follow-up visits. 81.3% of the cases who 
came for the appointment earlier than originally scheduled 
presented complaints compared to those who did not (p=0.005). 
Of the cases who presented recurrence, 12.9% attended an 
appointment late and those who did not present recurrence, 
47.6% were late for the appointment (p=0.006). Conclusion: It 
is seen that the patients who came for an earlier appointment 
presented more complaints and were associated with the 
positive result of the exams carried out. The patients who had 
recurrence and came for an earlier appointment did not present 
a statistically significant difference in recurrence-free survival. 
It was observed that distance was not a predominant factor 
in late attendance at appointments. Level of Evidence II, 
Retrospective Study.
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INTRODUCTION
Childhood cancer is rare and was estimated by the Brazilian 
National Cancer Institute (INCA), in the biennium 2008/2009, 
at about 9,890 new cases. In the United States, approximately 
one out of every 7,000 children from zero to 14 years of age is 
diagnosed with cancer per year. As is the case in developed 
countries, in Brazil cancer already represents the second cause 
of mortality proportionally among children and adolescents 
aged from 1 to 19 years, in all regions.1
Osteosarcoma (OS) is the most common primary malignant 
bone tumor.2 It is defined by the presence of malignant mesen-
chymal cells that produce osteoid or immature bone.3
The incidence of OS in the population in general is only 2-3 
cases/million people per year, but in adolescents the rate 
reaches peaks of 8 to 11 cases/million youths aged between 15 
and 19 years.4 In Brazil the estimate is 350 cases/year up to the 
age of 20 years,5 corresponding, together with Ewing’s sarcoma, 
to 5% of childhood cancers.6 In the United States, approximately 
560 children and adolescents are affected annually.7 Information 
from the population-based cancer records (RCBP) suggests that 
the incidence of osteosarcoma is higher in the black population 
of the USA, Italy, Germany and Spain.8 In Brazil, the incidence 
of osteosarcoma, in the age bracket between 10 and 14 years, 
was higher in the RCBP of São Paulo.9 At present, the average 
rate of incidence of childhood cancer in our country is 154.3 per 
million, with higher rates found in children aged from 1-4 years. 
Among adolescents from 15-19 years of age, the highest rates 
are in São Paulo (264 per million), Goiânia (251 per million) and 
Porto Alegre (229 per million).10
Osteosarcoma patients present a survival rate of up to 70% at 
five years11 for non-metastatic case and global survival of up 
to 80%.12 When they relapse, this survival reaches 20% at one 
year, and may reach 40% at five years, when complete resection 
of pulmonary metastases is possible.13 Most survivors will have 
good quality of life after adequate treatment; moreover, nowa-
days the cure does not just target the absence of disease, but 
a biopsychosocial cure and reduction of the risk of sequelae 
in the long term.14
Therefore, this study aims to evaluate the post-treatment follow-
-ups of pediatric osteosarcoma patients and to determine the 
sociodemographic, clinical and treatment-related characteristics 
that interfere in the post-treatment follow-up of these patients.
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MATERIALS AND METHODS
It is a retrospective study carried out at Fundação Pio XII – 
Hospital de Câncer de Barretos (HCB) with the patients treated 
for osteosarcoma, by the Pediatric Department in the period 
between January 2000 and July 2006. 
The data were collected through a clinical chart previously de-
fined according to the institution’s standards. This chart was 
completed by the researcher responsible for the study, through 
a review of the patient’s medical records in the Medical Archive 
and Statistics Service (SAME) of the Hospital. The data were 
subsequently typed in a specific database, using the Statistical 
Package for Social Science for Windows version 17.0 (SPSS 
17.0). The variables were distributed in categories, and updated 
with information taken from each clinical chart. 
The sociodemographic characteristics were collected from a 
registration form applied when the patient is admitted to the 
hospital. The other information was collected after a detailed 
review of the records. The collection form contained sociode-
mographic information (sex, ethnic group, age, place of birth, 
origin and distance), taking distance to mean the time con-
sumed in traveling from the municipality of residence to Hospital 
de Câncer de Barretos, considered near when less than three 
hours and far when more than three hours, and clinical informa-
tion (tumor grade, diagnosis, treatment and patient evolution).
The descriptive analysis of the data was performed by means 
of absolute and relative frequencies, measures of central ten-
dency (mean and median) and dispersion (standard deviation, 
minimum and maximum). The chi-square test of association 
was used for the analysis of qualitative variables, while Fisher’s 
exact test was used in the case of the variables that presented 
boxes with values of less than or equal to five.
The Kaplan-Meier product limit estimator was used in the patient 
survival analysis, and the comparison of curves was executed 
using the log rank test. Global survival time was calculated 
between the end of the treatment and the patient’s final status 
(alive; death). As regards disease-free survival, the time was 
evaluated between the end of treatment and the appearance of 
recurrence, emphasizing that only patients without metastasis 
at the beginning of the study were considered for this analysis.
For all the statistical analyses we assumed a descriptive level 
of 5%. The collected data were typed and analyzed in the SPSS 
program, version 17.0 for Windows.
The project study was approved by the Institutional Review Board 
of Hospital de Câncer de Barretos and by the committee of ethics 
of the School of Medicine of Universidade de São Paulo.
RESULTS
Of the 52 patients assessed and treated for osteosarcoma, 
during the follow-up in the Pediatric Department of HCB, 42 
where white (80.8%), 32 male (61.5%) and 28 were over 15 
years of age (53.8%).
According to origin, in the sample that encompassed eight 
Brazilian states, namely São Paulo, Rondônia, Minas Gerais, 
Mato Grosso, Mato Grosso do Sul, Goiás, Alagoas and Piauí, 
48.1% of the patients came from the state of São Paulo. As 
regards mileage, 65.4% of the patients lived far from HCB, i.e., 
a distance of more than three hours, while 26.9% of the patients 
spent from 4 to 21 hours traveling to the hospital.
As concerns the clinical characteristics, note that 36 (69.2%) 
of the patients evaluated did not present metastases upon 
diagnosis and in the others pulmonary metastasis represented 
23.1%, while only 1.9% presented bone metastasis. Of the 52 
patients evaluated, 59.6% presented recurrence and among 
these 34.6% were pulmonary.
Characteristics of patient appointments
The average quantity of appointments held per patient was 
4.8 (sd=3.5), with a maximum of 18 appointments. Among the 
appointments, 25 were held earlier than the scheduled date, 
and 23 were held on a later date.
The complaint observed in the appointments was associated 
with positive radiological examination, while in the appointments 
where complaints were reported, 53.8% had positive results. On 
the other hand, of the appointments without reports of com-
plaints, only 17.3% presented positive results (p<0.001). During 
follow-up, 81.3% of the patients who brought the appointment 
forward presented some complaint, when compared with those 
who did not bring the appointment forward, representing a sta-
tistically significant association (p=0.005). There was no sta-
tistically significant association between the demographic and 
clinical characteristics and early appearance at the appointment.
The presence of recurrence also showed statistically significant 
association with late attendance to appointments. Of the pa-
tients who presented recurrence, 12.9% were late in attending 
a particular appointment, while among the patients without re-
currence, 47.6% were late in attending a particular appointment 
(p=0.006). The presentation of complaints at any appointment 
is associated with early attendance at appointments. In the 
appointments where the patients presented complaints, 35% 
arranged an earlier appointment, while among the patients who 
did not present complaints this percentage was 5% (p<0.001). 
In the appointments where some patients arrived late, 54.5% of 
the patients were lodging away from home (p=0.010).
Analysis of survival
The global survival of the patients seen with osteosarcoma at 
HCB was 98.1% at 12 months; 78.7% at 24 months; 62.4% at 
36 months; and 41% at 60 months. (Figure 1) The event-free 
survival was 72% at 12 months; 41.4% at 24 months; and 36.2% 
at 36 and 60 months. (Figure 2)
For the patients with early attendance of appointments, the 
recurrence-free survival of 12, 24 and 36 months, was 76.9%, 
49.9% and 37.4%, respectively. While in the patients who did 
not attend the appointment early, it was 69.3% at 12 months; 
36.6% at 24 and 36 months, not presenting statistically signifi-
cant difference (p=0.625). (Figure 3)
DISCUSSION
The follow-up of the selected patients was performed by the 
same medical team and took place in a specialized hospital, 
with multidisciplinary training, use of equipment of controlled 
quality, reliable imaging exams and conditions for application 
of a single treatment protocol, contributing to the data reliability.
There are also disadvantages such as the likely bias, since 
the evaluation involves preexistent data from medical records, 
submitting to the risks of incomplete annotation. Another disad-
vantage is the small number of patients involved in the study.
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oncology team, easy access to the scheduling of new cases 
and the prevention program established by HCB, which reaches 
faraway states, such as Rondônia, which is the state with the 
second highest patient origin percentages in the study.
According to an analysis carried out by Camargo et al.10 the 
incidence of osteosarcoma remains higher in the state of São 
Paulo, as cited previously, by Parkin et al.9, and also confirmed 
by this study. However, the ideal model would be the multicenter 
trial, which would validate all the results found.
There are various national studies related to osteosarcoma 
(treatment, recurrence, results of the Brazilian Cooperative 
Group), but not exclusively geared towards the follow-up of 
osteosarcoma, from the point of view of a single institution, as 
in the present study.
One of the main studies is that of Castro et al.15, which gives an 
account of the experience of the pediatric oncology service of 
Santa Casa de Misericórdia de São Paulo with osteosarcoma. 
The objective of this study was to describe the clinical labora-
torial characteristics of 60 cases of children and adolescents 
with osteosarcoma, determining the rates of event-free survival 
and of global survival. The results were similar to those of this 
study and of international medical literature, and the authors 
also reached the conclusion that an early diagnosis in addition 
to further studies to improve handling and treatment geared 
towards improvement of quality of life are both essential. In-
ternational medical literature explains that adolescents are the 
most affected and that this disease is more common in the 
second decade of life, i.e., individuals in their twenties.16
It is known that, nowadays, the cure is not focused on the 
disease alone, but also on quality of life after treatment, even 
though this is related to the late effects of the initial therapy. 
Accordingly, the development of appropriate long-term follow-
-up strategies for cancer survivors is becoming more and more 
necessary.17 There are numerous US and European studies 
related to quality of life of the osteosarcoma survivor, through 
various types of evaluation. In the study by Renard et al.18 a 
scoring system of the Musculoskeletal Tumor Society was used 
to demonstrate better function of the lower limbs in patients who 
had undergone conservative surgery, instead of amputation.18 
However, other researchers did not find any differences in the 
result between these two groups, as is the case of Nagarajan 
et al.19, who did not find any differences of functional result in 
528 patients from the Childhood Cancer Survivor Study, using 
the TESS (Toronto Extremity Salvage Score) scale.
This scale consists of a self-applicable questionnaire, with 30 
questions assessing performing in daily activities, where a high 
score corresponds to a high functional level.20
The ideal treatment for osteosarcoma is polychemotherapy and 
surgery, since when relapse occurs, recovery is limited and the 
survival is very poor, as low as 20%, depending on the type of 
relapse, the majority of which are pulmonary.21 It is known that the 
treatment of pulmonary relapse should be imperative when pos-
sible, since the survival of patients with resection of pulmonary 
metastases is very expressive, as shown by Bacci et al.,22 who 
evaluated 235 patients with relapse after neoadjuvant therapy; 
among the patients treated with surgery, a cure was achieved 
in 25% of the sample. Continuing with this study, Briccoli et al.23 
reaffirmed the data with 323 patients with osteosarcoma, con-
cluding that in the patients with resectable pulmonary disease 
Figure 1. Accumulated global survival of patients treated for oste-
osarcoma.
Source: Pediatric Department, Hospital de Câncer de Barretos.
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Figure 2. Disease-free survival of patients treated for osteosarcoma.
Source: Pediatric Department, Hospital de Câncer de Barretos.
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Figure 3. Disease-free survival of patients treated for osteosarcoma, 
stratified according to early appointment attendance.
Source: Pediatric Department, Hospital de Câncer de Barretos.
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As described previously with regards to the rarity of osteosar-
coma, the limitation of the casuistry is explicit, in spite of the 
fact that the study was developed in one of the centers with the 
highest rates of OS in the country. Some of the main hypothe-
ses for the expressiveness at HCB in relation to the number of 
patients enrolled in the trial are the reference of the orthopedic 
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treated with adjuvant and neoadjuvant chemotherapy, thora-
cotomy should always be considered, regardless of the number 
of previous resections.
Approximately 50% of OS recurrences occurred within 18 months 
after the end of therapy and only 5% developed recurrences after 
five years. Ferrari et al.24 sought to identify predictive factors 
in the late relapse of non-metastatic osteosarcoma. The study 
was carried out over a period of 14 years, at the Rizzoli Institute, 
comparing 2 groups of patients: those with late relapse (>4 
years of follow-up) and those with early relapse. Late relapse 
was detected in 3.7% of 648 patients from the study. Complete 
surgical resection was accomplished in 79% of these patients 
with late relapse and post-relapse survival was 65%, compared 
with the 20% of survival in the patients with early relapse. LDH, 
type of surgery and histological response did not significantly 
differ between the patients with early and late relapse. No clinical 
predictive factors of late relapse were identified, thus a prolonged 
follow-up is recommended for all the patients. In another two 
large series, the most common sites of the disease were: lung 
(65.8%), bone (8-10%), local (4-7%) and combined (10-15%), 
also concluding that the control of recurrent OS depends on 
the complete surgical resection of the affected site. If surgery is 
not possible, progression and death are certain. Therefore, the 
most important prognostic factor in the first relapse is complete 
resection, with a survival rate, at five years, of 20 to 45% for 
pulmonary metastases and of 20% for other sites. In this sample, 
pulmonary recurrence was also more frequent, yet without 
access to the data on resectability and continuity of treatment, 
since the study ends at the time of recurrence.24
What is more challenging in the detection of recurrence is not 
the diagnosis in symptomatic patients, as these visited the 
hospital before the scheduled date, when necessary, but in-
stead, asymptomatic patients diagnosed with recurrence in the 
routine appointment and symptomatic patients who for some 
reason did not seek medical care at an early stage. There is a 
high proportion of those who did not reschedule an appoint-
ment for an earlier date and presented recurrence, in a ratio of 
almost 2:1. Thus the conclusion is that it is necessary to take 
complaints from the patient and their family seriously, always 
bringing appointments forward when the complaints are perti-
nent. Therefore, further studies are necessary to detect the real 
motive of those who presented recurrence, had no complaints 
and did not reschedule the appointment for an earlier date; and 
those who presented recurrence, had complaints and did not 
arrange for an earlier appointment.
Several factors are apparently involved in the delay of 
the diagnosis and some of them continue to be involved 
during follow-up, such as distance to the specialized center, 
transportation and lodging conditions, besides availability for 
patient examinations. In the patients from the studied sample, 
it was verified that of those who postponed their appointment, 
the majority depended on lodgings. In view of this information, 
it is being discussed whether the postponements occurred 
due to delay in the release of the funds allocated to traveling 
costs by the Treatment Outside the Home – TOH system, which 
can result from delay of medical report, or due to incomplete 
reports or shortage of public funds for care provision. It could 
also occur as a result of the postponement of the examination by 
the Radiology Department due to breakage of apparatus or any 
other cause. The only certainty is related to the accommodation 
vacancy, since no patient belonging to the service attends 
an appointment late for this reason, as when there are no 
vacancies, the service is responsible for the allocation for 
patients. Discussing these hypotheses, it is necessary to know 
the real role of the TOH. This body, created by Administrative 
Ruling no. 55, of the Department of Health Care (Ministry of 
Health), constitutes the legal instrument that ensures, through 
SUS (Unified Health System), that medical treatment is provided 
to patients with diseases that are untreatable in the municipality 
of origin, due to lack of technical conditions.25
It is observed that the use of TOH resources is subject to an 
extensive bureaucratic process that depends on several factors, 
especially on the familiarity of the physician from that body with 
pediatric oncology, as this individual is responsible for evalua-
ting the need for adequate post-treatment follow-up.
The second discussion concerns the purchasing power of each 
state, as it is no use patients having the right to receive treatment 
outside their place of abode if the state does not have funds to 
provide the medical care. Due to the vastness of our country, there 
are places that do not have minimum levels of access to health, 
to culture or any other information, because social exclusion also 
exists in south and southeast Brazil, thus complicating the post-
treatment follow-up program, confirming what was revealed in 
the study, i.e., that distance does not constitute the only cause of 
late attendance of appointments. There are no patients either at 
HCB, or rather, in this study, who come from one of the 10 cities 
classified as the poorest in the country, evaluated by the social 
exclusion index (SEI), although there are states of origin such as 
the state of Piauí, located north of the Tropic of Capricorn, which 
suffers even more with social exclusion. 
The SEI data reveal that 2,290 Brazilian cities, equivalent to 42% 
of the total municipalities, which contain 21% of the country’s 
population, exhibit high rates of social exclusion. On the other 
hand, only 200 cities (3.6% of the total), present an adequate 
standard of living.26 More than 25% of Brazilians live in precari-
ous conditions, with a low income, without formal employment 
and with limited access to education. According to the SEI, the 
data reveal that a historical scenario of exclusion appears to be 
firmly established in the north and northeast regions, hindering 
the follow-up and adequate treatment of cancer in general.
The third discussion is related to the postponement of the radio-
logical examinations, where the medical team often becomes 
aware of the situation only when they detect the patient’s absence 
at the scheduled appointment. A backup mechanism should be 
created for this solution, since many asymptomatic patients, with-
out evidence of urgency, can be jeopardized due to failure in early 
detection of recurrence. As regards the symptomatic patients, 
who arrive at the hospital and need to have urgent exams, but 
cannot wait for the maintenance of radiology equipment, it is a 
philosophy of HCB to consider them a top priority, performing the 
necessary examination anyhow.
Having covered the social and operational points, which may 
interfere in the delay of the recurrence diagnosis, it is known 
that the early examination of pulmonary recurrence will interfere 
mainly in the quality of life of the patient, since as it is resect-
able, there is an improvement in the survival quality, although 
not in a statistically significant manner, as seen in this study, 
where the recurrence-free survival was no different from those 
Acta Ortop Bras. 2012;20(4): 235-9
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that presented recurrence and did not come for an appointment 
earlier than the original date.
This means that further molecular studies are necessary for 
us to increasingly manage to obtain a detailed patient profile, 
as is the case of tumor activity markers, which can interfere 
in the response to treatment and in relapse, allowing an in-
vestment in new multicenter studies for the discovery of new 
drugs and new markers. Faced with the difficulty of response 
in patients presenting recurrence, Zhao et al.27 published a 
study that assessed the efficacy of pirarubicin in association 
with chemotherapy in patients with pulmonary metastases. That 
study evaluated the effect and adverse reactions of pirarubicin 
(THF) in association with cisplatin or ifosfamide and analyzed 
the relation between therapeutic effect and the expression of 
P-glycoprotein and topoisomerase-II. There was no difference in 
the global survival and in the progression-free survival between 
the use of cisplatin and ifosfamide, but it had an effect on the 
negativation of P-glycoprotein and/or topoisomerase-II. There-
fore, for patients with pulmonary relapse, THF in association 
with chemotherapy was effective.27
It is indisputable that the follow-up of cancer patients is neces-
sary, yet the form and frequency give rise to doubt. Several 
formulas were developed in the attempt to discover the best 
follow-up, such as the Collins formula, which, however, does 
not apply to all types of tumor, including OS.28 There is no 
consensus regarding a follow-up plan for OS, and authors only 
agree on its importance.4
Therefore, in view of the urgent need for follow-up of patients 
treated for OS, several aspects still need to be studied in 
depth, such as the cost and effectiveness of childhood cancer 
treatment, and consequently, of the post-treatment program and 
even of the palliative care. It is known that the economic weight 
of cancer is substantial, yet it is possible to estimate direct 
and indirect costs for a large number of cancer patients, using 
databases related to the sociodemographic, demographic, and 
geographical characteristics, besides those of the type that 
would improve research and the quality of treatment, of follow-
up and even of the act of dying.29
CONCLUSION
Hence it is concluded that the complaint observed in the 
appointments is associated with the positive test result, 
without any association between the demographic and clinical 
characteristics with regard to early appointment attendance. The 
patients who did not present recurrences took longer to schedule 
an appointment than those presenting recurrence. The evaluation 
showed a statistically significant association between the patients 
who brought any appointment forward and those who had 
complaints. In the appointments with cases of late attendance, 
54.5% of the patients were staying at lodgings.
Acta Ortop Bras. 2012;20(4): 235-9
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